Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 241

Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Pavlos Msaouel speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the combination of sitravatinib and nivolumab for the treatment of advanced clear cell renal cell cancer (aCCRCC) in patients who have progressed on prior VEGF-targeted therapy.

He explains the background of this early phase I/II study, along with the main results achieved in this study.

Dr Msaouel concludes that this combination did to demonstrate any unexpected safety signals and achieved higher objective responses and longer disease control compared to the use of nivolumab alone.


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation